GLP-1 treatments for type 2 diabetes have been on the market for nearly 20 years. The newer generation — such as Novo Nordisk's Ozempic and Eli Lilly's Mounjaro — are far more effective at controlling blood sugar levels and inducing weight loss. Ozempic was the first of the newer generation in the class to be approved in 2017.In the study published in the medical journal JAMA Network Open, researchers examined the medical records of 1.
The study found that the patients treated with a GLP-1 therapy instead of insulin 'had a significant risk reduction' in 10 of those cancers.The findings are 'preliminary evidence of the potential benefit' of GLP-1 drugs for cancer prevention in high-risk population, the researchers concluded. They also said studies of the newer generation of these medicines for their cancer-preventive effects were warranted.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: gmanews - 🏆 11. / 68 Read more »